Examples of using Cml in English and their translations into Vietnamese
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
CML in future years.
Want more information on the CML?
Why is CML a rare disease?
It explains the factors that may increase the chance of developing CML.
In CML, this process doesn't work properly.
It explains areas of scientific research currently going on for CML.
The"Theme golden rose bow" cml theme is only available for phones with the cm launchers EX.
Drugs that target the BCR-ABL protein, such as imatinib(Gleevec®),are often very effective against CML.
The treatment options for accelerated phase CML depend on what treatments the patient has already had.
CML accounts for 10 to 15 percent of all types of leukemia, with the average age of diagnosis being 67.
Simply click“From File” and choose any Chemical Markup Language(. cml) formatted file to insert the chemical formula.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
One of the most important advantages of Tarkett laminate isconsidered to be a specific coating according to the technology. CML.
CML is a fairly slow growing leukemia, but it can also change into a fast-growing acute leukemia that is hard to treat.
Because I was collaborating with the other code groups- CDK, Bioclipse, Jmol, JSpecview, OpenBabel, etc-they adopted CML.
The dose of 340 mg/m2 daily is recommended for children with chronic phase CML and advanced phase CML(not to exceed the total dose of 800 mg).
The presence of immature white blood cells, or myeloblasts, in the blood andbone marrow is also used to stage AML and CML.
Now, in the present day a person who is suffering from CML that has Philadelphia chromosome, and is in remission after 2 years of treatment with Imatinib has the same life expectancy as someone who doesn't have Cancer.
As with other ATP competitive small molecule tyrosine kinase inhibitors,such as imatinib(Gleevec) in CML, patients rapidly develop resistance.
In 1998, at the request of the Transport Office of Corsica, CML la Meridionale began passenger services to the island, and increased its services to include ferries to Sardinia a year later.
With this drug, more than 90% of patients will be able to keep thedisease in check for at least five years,[30] so that CML becomes a chronic, manageable condition.
In CML, a genetic change takes place in an early(immature) version of myeloid cells- the cells that make red blood cells, platelets, and most types of white blood cells(except lymphocytes).
The discovery of molecular markers for cancer, the availability of cytogenetic analysis and other new tests, and a class of drugs known as tyrosine kinase inhibitors,meant that some people can be cured of CML with drugs.
The PACE(Ponatinib Ph+ ALL and CML Evaluation) pivotal phase II trial started enrolling patients in September 2010 and is designed to provide definitive clinical data for regulatory approval in this setting.
In his talk, he explained how some cancers such as chronic myeloid leukaemia(CML) could be diagnosed with just a blood sample these days because CML is characterised by a chromosomal abnormality which can be detected by cytogenetic analysis, a chromosomal analysis of blood.
Patients with CML currently receive front line therapies nilotinib and/or dasatinib though 22- 33% of patients discontinue therapy by two years due to adverse events, treatment failure and other causes.[citation needed].
Nilotinib, sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia(CML) which has the Philadelphia chromosome.[2] It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib.[2][2] It is taken by mouth.
The study demonstrated that in chronic-phase CML patients treated with ponatinib, 66 percent of patients in the trial achieved a major cytogenetic response, including 100 percent of patients who also had a T315I mutation.[citation needed].
Over four years, Lee's laboratory collected data from CML patients, measuring the strength of each patient's immune response, in the form of the numbers and the activity of the anti-leukemia T cells, at different times during imatinib therapy.
